MedPath

ASTRAZENECA UK LIMITED

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:2
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

130

NMPA:71
EMC:43
SFDA:12
+2 more agencies

Drug Approvals

Capivasertib Tablets

Product Name
荃科得
Approval Number
国药准字HJ20250046
Approval Date
Apr 15, 2025
NMPA

Capivasertib Tablets

Product Name
荃科得
Approval Number
国药准字HJ20250047
Approval Date
Apr 15, 2025
NMPA

Durvalumab Injection

Product Name
英飞凡
Approval Number
国药准字SJ20190039
Approval Date
May 23, 2024
NMPA

Durvalumab Injection

Product Name
英飞凡
Approval Number
国药准字SJ20190038
Approval Date
May 23, 2024
NMPA

Anastrozole Tablets

Product Name
瑞宁得
Approval Number
国药准字HJ20140692
Approval Date
Dec 4, 2023
NMPA

Anastrozole Tablets

Product Name
瑞宁得
Approval Number
国药准字HJ20140691
Approval Date
Dec 4, 2023
NMPA

Bicalutamide Tablets

Product Name
康士得
Approval Number
国药准字HJ20140720
Approval Date
Nov 30, 2023
NMPA

Bicalutamide Tablets

Product Name
康士得
Approval Number
国药准字HJ20140719
Approval Date
Nov 30, 2023
NMPA

Selumetinib Hydrogen Sulfate Capsules

Product Name
科赛优
Approval Number
国药准字HJ20230045
Approval Date
Apr 28, 2023
NMPA

Selumetinib Hydrogen Sulfate Capsules

Product Name
科赛优
Approval Number
国药准字HJ20230044
Approval Date
Apr 28, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.